Cadila Healthcare Q2 net profit up 32 percent at Rs 503 crore

Published On 2017-11-15 04:30 GMT   |   Update On 2021-08-18 08:28 GMT

New Delhi: Drug firm Cadila Healthcare reported a 32.48 percent rise in its consolidated net profit to Rs 503.3 crore for the second quarter ended September 30, mainly on account of robust sales in the US and India.


The company had posted a net profit of Rs 379.9 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a BSE filing.


Consolidated total revenue from operations also rose to Rs 3,234 crore for the quarter under consideration as against Rs 2,403.5 crore in the same period a year ago.



The company's sales in the US rose by 66 percent to Rs 1,644 crore for the quarter ended September 30, Cadila Healthcare said.

The Indian formulations business also grew by 15 percent, excluding the excise duty, to Rs 895 crore, it added.


"During the quarter, the company launched four new products in the US, including Mesalamine delayed release 1.2 g tablets (generic version of Lialda) with a 180 days exclusivity," Cadila Healthcare said.

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News